Revisiting monoamine oxidase inhibitors

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 8, 2007, Pages 35-41

  Krishnan, K Ranga ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ATENOLOL; BROFAROMINE; CENTRAL DEPRESSANT AGENT; CLOMIPRAMINE; CLORGYLINE; COCAINE; DEXTROMETHORPHAN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; LITHIUM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NARCOTIC AGENT; NEFAZODONE; NORTRIPTYLINE; PETHIDINE; PHENELZINE; PLACEBO; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; APPLICATION SITE REACTION; ATYPICAL DEPRESSION; BIPOLAR DEPRESSION; BRAIN HEMORRHAGE; CHEESE; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DIET RESTRICTION; DRIED FOOD; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; ENZYME SPECIFICITY; FERMENTED PRODUCT; FOOD DRUG INTERACTION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERACTIVITY; HYPERPYREXIA; HYPERTENSION; HYPERTENSIVE CRISIS; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEIZURE; SEROTONIN SYNDROME; STROKE; TACHYCARDIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; DEPRESSIVE DISORDER; HUMANS; MONOAMINE OXIDASE INHIBITORS;

EID: 34547521484     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994;97:24S-32S
2. Crane GE. The psychiatric effects of iproniazid. Am J Psychiatry 1956;112:494-501
3. Loomer HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatry Res Rep Am Psychiatr Assoc 1957;135:129-141
4. Scherbel AL. The effect of isoniazid and iproniazid in patients with rheumatoid arthritis. Cleve Clin Q 1957;24:90-97
5. Nelson SD, Mitchell JR, Timbrell JA, et al. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 1976;193:901-903
6. Robinson DS. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull 2002;36:124-138
7. Petersen T, Dording C, Neault NB, et al. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:177-187
8. Thiery M. Clinical trial of the treatment of depressive illness: report to the medical research council by its clinical psychiatry committee. Br J Med 1965;1:881-886
9. Holschneider DP, Shih JC. Monoamine oxidase: basic and clinical perspectives. In: Psychopharmacology: The Fourth Generation of Progress. Nashville, Tenn: American College of Neuropsychopharmacology; 2000
10. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract 2004;10:239-248
11. Baker GB, Coutts RT, McKenna MF, et al. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci 1992;17:206-214
12. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17:1285-1297
13. Wecker L, Pacheco MA. A neurochemical perspective on monoamine oxidase inhibitors. Psychiatr Ann 2001;31:354-360
14. Robinson DS, Nies A, Ravaris CL, et al. Clinical pharmacology of phenelzine. Arch Gen Psychiatry 1978;35:629-635
15. Young WF, Laws ER, Sharbrough FW, et al. Human monoamine oxidase: lack of brain and platelet correlation. Arch Gen Psychiatry 1986;43:604-609
16. Mawhinney M, et al. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared to intestinal and hepatic tissues. J Pharm Pharmacol 2003;55:27-34
17. Wecker L, et al. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry 2003;54:1099-1104
18. Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972;5:393-408
19. Mann JJ, Aarons SF, Frances AH, et al. Studies of selective and reversible monoamine oxidase inhibitors. J Clin Psychiatry 1984;45:62-66
20. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999;20:226-247
21. Thase ME, Trivedi M, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219
22. Mallinger AG, Smith E. Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull 1991;27:493-502
23. Murphy DL, Aulakh CS, Garrick NA, et al. Monoamine oxidase inhibitors as antidepressants: implications for the mechanisms of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:545-552
24. Blier P, de Montigny C, Azzaro AJ. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther 1986;237:987-994
25. deMontigny C, Blier P. Modifications of monoaminergic system properties by MAOIs: basis for their therapeutic effect? In: Shader RI, ed. MAOI Therapy. New York, NY: Audio Visual Medical Marketing, Inc; 1988:5-12
26. Laux G, Volz HP, Möller HJ. Newer and older monoamine oxidase inhibitors: a comparative profile. CNS Drugs 1995;3(suppl 2):145-158
27. Waldmeier PC, Glatt A, Jaekel J, et al. Brofaromine: a monoamine oxidase-A and serotonin uptake inhibitor. Clin Neuropharmacol 1993;16(suppl 2):S19-S24
28. Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry 1994;55:24-25
29. Chouinard G, Saxena BM, Nair NP, et al. A Canadian multi-centre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAOI-inhibitor, in the treatment of major depression. J Affect Dis 1994;32:105-114
30. Laux G, Claussen W, Sofic E, et al. Clinical, biochemical and psychometric findings with the new MAO-inhibitors moclobemide and brofaromine in patients with major depressive disorder. J Neural Transm Suppl 1990;32:189-195
31. Bakish D, Bradwejn N, Nair N, et al. A comparison of moclebomide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl) 1992;106(suppl):S98-S101
32. Versiani M, Oggero U, Alterwain P, et al. A double-blind comparative trial of moclobemide v imipramine and placebo in major depressive episodes. Br J Psychiatry Suppl 1989 Oct;(6):72-77
33. Nair NP, Ahmed SK, Kin NM, et al. Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients. Acta Psychiatr Scand Suppl 1995;386:28-35
34. Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry 1996;168:149-157
35. Stabl M, Kasas A, Blajev B, et al. A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression. J Clin Psychopharmacol 1995;15:41S-45S
36. Schmitt H, Boissier JR, Giudicelli R. Centrally mediated decrease in sympathetic tone induced by 2-(2,6-dichlorphenylamino)-2-imidazole (ST 155, Catapresan). Eur J Pharmacol 1967;2:147-148
37. Gessa GL, Cuenca E, Costa E. On the mechanism of hypotensive effects of MAO inhibitors. Ann N Y Acad Sci 1963;107:935-944
38. Blackwell B, Marley E, Price J, et al. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967;113:349-365
39. Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese. Lancet 1963;54:733-734
40. Brown C, Taniguchi G, Yip K. The monoamine oxidase inhibitor-tyramine interaction. J Clin Pharmacol 1989;29:529-532
41. Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry Suppl 1989;6:38-45
42. Hendley ED, Snyder SH. Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy. Nature 1968;220:1330-1331
43. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993;53:84-88
44. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995;13:94-104
45. Cohen LJ. Rational drug use in the treatment of depression. Pharmacotherapy 1997;17:45-61
46. Georgotas A, McCure RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry 1986;21:1155-1166
47. Davidson JR, Giller EL, Zisook S, et al. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry 1988;45:120-127
48. Razani J, White KL. White J, et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment: a controlled trial. Arch Gen Psychiatry 1983;40:657-661
49. McGrath PJ, Stewart JW, Harrison W, et al. Treatment of cyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 1987;23:169-172
50. Bresnahan DB, Pandey GN, Janicak PG, et al. MAO inhibition and clinical response in depressed patients treated with phenelzine. J Clin Psychiatry 1990;51:47-50
51. Robinson DS, Lerfald SC, Bennett B, et al. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 1991;27:31-39
52. Georgotas A, McCure RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989;46:783-786
53. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
54. Parker G, Roy K, Mitchell P, et al. Atypical depression: a reappraisal. Am J Psychiatry 2002;159:1470-1479
55. Liebowitz MR. Depression with anxiety and atypical depression. J Clin Psychiatry 1993;52:10-14
56. Ravaris CL, Robinson DS, Ives JO. Phenelzine and amitriptyline in the treatment of depression: a comparison of present and past studies. Arch Gen Psychiatry 1980;37:1075-1080
57. Rowan PR, Paykel ES, Parker RR. Phenelzine and amitriptyline: effects on symptoms of neurotic depression. Br J Psychiatry 1982;140:475-483
58. Kayser A, Robinson DS, Yingling K, et al. The influence of panic attacks on response to phenelzine and amitriptyline in depressed outpatients. J Clin Psychopharmacol 1988;8:246-253
59. Liebowitz MR, Quitkin FM, Stewart WJ, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-137
60. Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine versus imipramine in the treatment of probably atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988;145:306-311
61. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 1990;47:935-941
62. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993;150:118-123
63. Thase ME, Rush AJ. Treatment resistant depression. In: Bloom F, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081-1097
64. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, 3: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11
65. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993;150:118-123
66. Nolen WA, Haffmans PMJ, Bouvy PF, et al. Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993;28:189-197
67. Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987;48:55-59
68. Van Vliet IM, Westernberg HG, Den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with broforamine: a double-blind placebo controlled study. Psychopharmacology 1993;112:483-489
69. Bakish D, Saxena BM, Bowen R, et al. Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol 1993;16(suppl 2):S77-S82
70. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51-59
71. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300
72. Charney DS, Woods SW, Nagy LM, et al. Noradrenergic function in panic disorder. J Clin Psychiatry 1990;51(suppl A):5-11
73. Nutt DJ, Glue P, Lawson C. The neurochemistry of anxiety: an update. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:737-752
74. Himmelhoch JM, Detre T, Kupfer DJ, et al. Treatment of previously intractable depressions with tranylcypromine and lithium. J Nerv Ment Dis 1972;155:216-220
75. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148:910-916
76. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, 4: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149:195-198
77. Larsen JK, Rafaelsen OJ. Long-term treatment of depression with isocarboxazid. Acta Psychiatr Scand 1980;62:456-463
78. Quitkin FM, McGrath P, Liebowitz MR, et al. Monoamine oxidase inhibitors in bipolar endogenous depressives. J Clin Psychopharmacol 1981;1:70-74
79. Clary C, Mandos LA, Schweizer E. Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants. J Clin Psychiatry 1990;51:226-231
80. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002;159:1869-1875
81. Amsterdam J. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003;64:208-214
82. Angst J, Amrein R, Stahl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol 1995;15(4 suppl 2):16S-23S